<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916978</url>
  </required_header>
  <id_info>
    <org_study_id>PRP - Menopausal women</org_study_id>
    <nct_id>NCT03916978</nct_id>
  </id_info>
  <brief_title>Ovarian Autologous-Platelet Rich Plasma Treatment (PRP) in Menopause.</brief_title>
  <acronym>PRP</acronym>
  <official_title>Estimation of Ovarian Rejuvenation and Reactivation After Autologous Platelet-rich Plasma Therapy in Menopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesis Athens Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genesis Athens Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous ovarian Platelet Rich Plasma (PRP) treatment may enable restoration of the
      menstrual cycle in menopausal women, and could offer therefore the possibility of pregnancy
      employing their own oocytes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific prospective clinical investigation, aims to answer whether autologous Platelet
      Rich Plasma (PRP) administrated into the ovaries can lead to regeneration and reactivation of
      the ovarian tissue in menopausal women.

      PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It
      is collected from peripheral veins and contains several growth factors such as vascular
      endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth
      factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate
      tissue proliferation and growth. Since many years, PRP has been used in several medical
      conditions in Orthopedics, Dermatology, Ophthalmology for wound healing. It's efficacy in
      ovarian rejuvenation and reactivation and endometrial regeneration has not been fully
      elucidated.

      The aim of this study is to evaluate the effectiveness of ovarian PRP injection, in order to
      rejuvenate and reactivate the ovaries with the ultimate goal of indicating a possible
      correlation between this mode of treatment and the reproductive effect in menopausal women.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restoration of the menstrual cycle</measure>
    <time_frame>6 months</time_frame>
    <description>Menstruation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FSH levels</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of FSH measured per month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AMH</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of AMH measured per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oestradiol</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of E2 measured per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LH</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of LH measured per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progesteron</measure>
    <time_frame>3 months</time_frame>
    <description>Serum levels of PRG recorded monthly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Folliculogenesis reactivation</measure>
    <time_frame>3 months</time_frame>
    <description>TVUS monitoring of the primordial and antral follicular count (AFC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Anovulatory Infertility</condition>
  <condition>Menopause</condition>
  <condition>Amenorrhea</condition>
  <arm_group>
    <arm_group_label>Group - PRP patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Menopausal women minimum 45 years of age, receiving ovarian PRP treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group - Placebo patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Menopausal women minimum 45 years of age, receiving ovarian placebo treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP</intervention_name>
    <description>Autologous Platelet-rich Plasma injection into the ovaries.</description>
    <arm_group_label>Group - PRP patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injected into the ovaries.</description>
    <arm_group_label>Control Group - Placebo patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Amenorrhea at least for 12 months

          -  Stopped HRT for at least 3 months

          -  Stopped Botanotherapy / Danazol for 3 months

          -  Willing to comply with study requirements

        Exclusion Criteria:

          -  Current diagnosis of cancer

          -  Ovarian inaccessibility

          -  Current or previous premature ovarian failure

          -  Endocrinologic disorders (Thyroid Dysfunction, Diabetes mellitus, Metabolic syndrome),

          -  BMI&gt;30 kg/m2

          -  Systematic autoimmune disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mara Simopoulou, PhD</last_name>
    <phone>+306979234100</phone>
    <email>marasimopoulou@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agni Pantou, MD, PhD Candidate</last_name>
    <phone>+306974447702</phone>
    <email>agni.pantou@genesisathens.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genesis AC</name>
      <address>
        <city>Athens</city>
        <zip>15232</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agni Pantou, MD, PhD Candidate</last_name>
      <email>agni.pantou@genesisathens.gr</email>
    </contact>
    <investigator>
      <last_name>Agni Pantou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Pantos, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian rejuvenation</keyword>
  <keyword>Ovarian reactivation; ovulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

